Hypofractionated Brain Radiationcavity

Status Active, not recruiting

Clinical Trial Summary

Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases

Clinical Trial Description

Patients with limited number of brain metastases from solid tumors are at high risk of local recurrence after surgical removal of the tumor mass. The standard Whole-brain radiotherapy (WBRT) demonstrated to reduce the risk of recurrence without improving survival. At the same time WBRT have substantial acute and late toxicity. Preliminary experiences with Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity indicate promising local control and good tolerance. This attitude was only partially explored in prospective trials. In this research patients with limited number of brain metastases and controlled systemic disease will be treated, with such a stereotactic irradiation, at the same time with evaluation of the local control (Primary endpoint) by repeated MRI and of quality of life, neurologic functionning (with a battery of thsts, e.g. MMSE, QLQ-C30, EORTC BN-20) as well as overall survival as secondary endpoints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03561896
Study type	Interventional
Source	Oncology Institute of Southern Switzerland
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 2015
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05428852` - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases	N/A
Recruiting	`NCT05559853` - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting	`NCT05689619` - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)	N/A
Recruiting	`NCT04197297` - Brain Imaging Biomarkers in Patients With Brain Metastasis	Phase 2
Recruiting	`NCT04397978` - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated	`NCT04434560` - Neoadjuvant Immunotherapy in Brain Metastases	Phase 2
Active, not recruiting	`NCT05095766` - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting	`NCT05012254` - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases	Phase 2
Recruiting	`NCT05789589` - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT06280300` - Multi-disciplinary Care for Brain Metastases	N/A
Recruiting	`NCT06047379` - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Phase 1/Phase 2
Completed	`NCT03896555` - Intrafractional Head Movement During Radiosurgery
Terminated	`NCT03789149` - Focal Intraoperative Radiotherapy of Brain Metastases	Phase 2
Recruiting	`NCT04343157` - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases	Phase 2
Recruiting	`NCT04711824` - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	Phase 1/Phase 2
Recruiting	`NCT05793489` - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin	N/A
Recruiting	`NCT04461418` - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases	Phase 2
Active, not recruiting	`NCT03818386` - Radiotherapy of Multiple Brain Metastases Using AGuIX®	Phase 2
Active, not recruiting	`NCT05087095` - Managing Distress in Malignant Brain Cancer	N/A
Recruiting	`NCT04396717` - Safety Study of Pritumumab in Brain Cancer	Phase 1